TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
2010
Size (employees)
446 (est)
TESARO was founded in 2010 and is headquartered in Waltham, US

TESARO Office Locations

TESARO has an office in Waltham
Waltham, US (HQ)
3300 1000 Winter St

TESARO Data and Metrics

TESARO Financial Metrics

TESARO's revenue was reported to be $44.8 m in FY, 2016 which is a 14040% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

44.8 m

Revenue growth (FY, 2015 - FY, 2016), %

14040%

Net income (FY, 2016)

(387.5 m)

EBIT (FY, 2016)

(371 m)

Market capitalization (25-May-2017)

8.3 b

Closing share price (25-May-2017)

155.7

Cash (31-Dec-2016)

785.9 m
TESARO's current market capitalization is $8.3 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

317 k44.8 m

Revenue growth, %

14040%

Operating expense total

92.4 m167.3 m236.4 m415.8 m

EBIT

(92.4 m)(167.3 m)(236 m)(371 m)

EBIT margin, %

(74461%)(828%)

Interest expense

3.8 m15.4 m16.5 m

Interest income

83 k24 k48 k1.4 m

Income tax expense

1.5 m

Net Income

(92.4 m)(171 m)(251.4 m)(387.5 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

130.3 m256.9 m230.1 m785.9 m

Accounts Receivable

679 k5.3 m

Inventories

1.1 m14.7 m

Current Assets

134.3 m258.6 m236.5 m814.8 m

PP&E

440 k1 m2.8 m6.6 m

Total Assets

135.6 m263.9 m255.3 m839.8 m

Accounts Payable

1.9 m6.1 m8 m5.2 m

Current Liabilities

12.4 m24.4 m46.7 m76.8 m

Additional Paid-in Capital

302.6 m474.6 m688.8 m1.6 b

Retained Earnings

(179.5 m)(350.5 m)(601.9 m)(990.7 m)

Total Equity

123.2 m124.1 m86.9 m611.2 m

Financial Leverage

1.1 x2.1 x2.9 x1.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.4 m)(171 m)(251.4 m)(387.5 m)

Depreciation and Amortization

179 k349 k1 m3.1 m

Accounts Receivable

(679 k)5.3 m

Inventories

(1.1 m)14.7 m

Accounts Payable

(1.3 m)4.2 m1.9 m5.2 m

Cash From Operating Activities

(84.9 m)(117.5 m)(194.5 m)(287.7 m)

Purchases of PP&E

(400 k)(1 m)(2.3 m)(2.9 m)

Cash From Investing Activities

(2.3 m)(25.9 m)(19.8 m)(23.3 m)

Cash From Financing Activities

92.1 m269.9 m187.6 m866.9 m
Numbers are in $, USDY, 2016

Revenue/Employee

376.7 k

Financial Leverage

1.4 x

TESARO Operating Metrics

FY, 2016

Products

2

Countries

7

Patent Portfolios

3

TESARO Market Value History

TESARO Online and Social Media Presence

TESARO News and Updates

TESARO Company Life and Culture

You may also be interested in